Achieve Life Sciences Inc. has made significant strides in its mission to combat nicotine addiction, with a proposed public offering, partnership with Omnicom, and FDA submission for its cytisinicline treatment.

Achieve Life Sciences reported a GAAP EPS of -$0.37 for Q1 2025, aligning with expectations, as the company focuses on developing and commercializing its cytisinicline program for nicotine addiction.